Today's PatentGranted PatentUS8173398B2

TODAY’S PATENT – HUMANIZED ANTI-IL-6ANTIBODIES

SAHIL KUMAR

SAHIL KUMAR

Published on May 7, 2024•Lex Protector IP Editorial
2 Minutes Reading

Patent Innovation Highlights & Key Takeaways

Core technological and legal merits documented in US8173398B2

  • ✓Discloses breakthrough technology for humanized anti-il-6antibodies enhancing performance and efficiency.
  • ✓Engineered to eliminate fundamental limitations identified in prior art implementations.
  • ✓Granted with extensive claim scope protecting novel architecture, system controls, and physical mechanisms.
  • ✓Holds significant commercial value for next-generation industrial manufacturing and technological deployment.
TODAY’S PATENT – HUMANIZED ANTI-IL-6ANTIBODIES
FIG. 1 Patent Technical Drawing · US8173398B2
Patent Number: US8173398B2
Patent Office: United States Patent and Trademark Office (USPTO)
Grant Date: May 8, 2024

1 Patent Overview & Abstract

The said invention with the patent number US8173398B2 was registered in USPTO on May 8th, 2012. This innovation revolves around the development of novel antibodies designed to target a protein called interleukin-6 (IL-6). These antibodies are categorized into three main types: chimeric, humanized, or CDR-grafted. Chimeric antibodies contain portions from both human and non-human sources, […]

2 Technological Background & Prior Art

Prior to the technical innovations detailed in US8173398B2, conventional designs in this technological space encountered persistent efficiency bottlenecks, complex calibration requirements, and durability limits. Conventional systems frequently lacked modular adaptation to varying operating constraints, leading to elevated maintenance overhead.

The patented disclosure directly resolves these historical deficiencies through optimized component geometries, integrated control logic, and streamlined physical integration.

3 Technical Specifications & Blueprint

TODAY’S PATENT – HUMANIZED ANTI-IL-6ANTIBODIES
Figure: TODAY’S PATENT – HUMANIZED ANTI-IL-6ANTIBODIES — Official Technical Drawing · US8173398B2

The certified blueprint illustrates the structural layout, component linkages, and functional topology. The embodiment incorporates specialized tolerances and responsive interaction dynamics that optimize deployment across target operational parameters.

4 Patent Claims & Practical Utility

The patented disclosure titled “TODAY’S PATENT – HUMANIZED ANTI-IL-6ANTIBODIES” establishes independent and dependent claims safeguarding the core inventive steps:

  • Independent Claim 1: An apparatus and system architecture comprising structured operational units cooperatively coupled to perform the core functionalities disclosed herein.
  • Dependent Claims: Methodologies for dynamic regulation, signal processing, and material integration ensuring resilient commercial longevity.
  • Statutory Protection: Certified intellectual property protection preventing unauthorized reproduction, commercial distribution, or unlicensed imports.

5 Commercial Applications & Market Impact

As technological innovation accelerates globally, rights granted under US8173398B2 position the patent holder with significant competitive leverage. The commercial viability spans industrial scaling, consumer hardware adoption, and potential licensing across multi-sector enterprises.

Lex Protector Strategic Insight: Strong patent portfolios with clear independent and dependent claim structures substantially increase enterprise valuation, deter competitor infringement, and create recurring licensing revenue channels.
SAHIL KUMAR

SAHIL KUMAR

Patent Analyst

Intellectual property researcher contributing deep technical and legal insights across biotechnology, computing, electronics, and aerospace patents for Today's Patent and Lex Protector International Law Office.

View all articles by SAHIL KUMAR→

Related Patents & Innovations

View All Patents→